Abstract 1519P
Background
In the phase-3 NAPOLI-1 trial (NCT01494506), liposomal irinotecan (nal-IRI) with 5-fluorouracil/leucovorin (5-FU/LV) improved survival outcomes in mPDAC patients pre-treated with gemcitabine-based regimens. However, real-world data on clinical benefits and safety are scarce. This study gathered real-world evidence on patients who survived ≥1 year after initiation of nal-IRI following treatment with a gemcitabine-based regimen.
Methods
This retrospective non-interventional study was conducted in Austria, Belgium, Germany, Japan, and South Korea. Data were collected from mPDAC patients who received ≥1 nal-IRI/5-FU/LV after a gemcitabine-based chemotherapy from January 2018 to December 2021 and surviving >1 year after initiation of the combination. Descriptive analyses, treatment patterns summaries, and overall survival (OS) determination via Kaplan-Meier method were conducted.
Results
Of the 163 patients analyzed, 131 (80.4%) were deceased and 32 (19.6%) alive. Ten (6.1%) patients initiated nal-IRI in 1L, 123 (75.5%) in 2L, and 30 (18.4%) in ≥3L. The median number of nal-IRI cycles received was 14 (min-max: 1-108). The median treatment duration from initiation to end of treatment was 8.4 (min-max: 0-45) months. At data cut-off, 139 (85.3%) discontinued nal-IRI, with 98 (70.5%) of them due to progression. Overall, 44 (27.0%) experienced grade 3/4 adverse drug reactions. Median OS from mPDAC diagnosis and nal-IRI initiation was 34.3 (CI 30.4-37.5) and 21.0 (CI 19.0-23.7) months, respectively. Table: 1519P
Patients characteristics
N=163 | |
Sex, n (%) | |
Male | 85 (52) |
Female | 78 (48) |
Mean (SD) age at mPDAC diagnosis | 66.3 (8.6) |
Metastasis site, n (%) | |
Liver | 73 (44.8) |
Lung | 54 (33.1) |
Lymph node | 40 (24.5) |
Previous treatment, n (%) | |
Surgery | 106 (65) |
Radiation | 47 (27.6) |
Number of systemic treatments, median (min-max) | 4 (2-8) |
Conclusions
In mPDAC, subgroups of patients with favorable OS exist, but are poorly understood. This real-world cohort had a median OS comparable to that of long-term treated NAPOLI-1 survivors, yet older with more prior lines of therapy. This real-world cohort will allow for further analyses exploring the underlying mechanisms of this population of long-term survivors.
Clinical trial identification
NCT06155136.
Editorial acknowledgement
Nihar Masurkar and Sophia Costanza-Mcdonald, Oracle Life Sciences for medical writing support.
Legal entity responsible for the study
Servier.
Funding
Servier.
Disclosure
M. Ueno: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical, Incyte, MSD, Nihon Servier, Ono Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, J-Pharma, Eisai, Yakult Honsha; Financial Interests, Personal, Advisory Board: Nippon Boehringer Ingelheim, Novartis; Financial Interests, Institutional, Local PI: Astellas Pharma, AstraZeneca, Chugai Pharmaceutical, DFP, Daiichi Sankyo, Eisai, Incyte, MSD, Merck Biopharma, Ono Pharmaceutical, Taiho Pharmaceutical, Novartis, J-Pharma, Novocure, Chiome Bioscience. C. Yoo: Financial Interests, Personal, Invited Speaker: Bayer, Celgene, Eisai, Ipsen, Servier, Roche, Novartis; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Research Grant: AstraZeneca, Bayer, Servier; Financial Interests, Institutional, Research Grant: Genentech. T. Macarulla Mercade: Financial Interests, Personal, Advisory Board: Ability Pharmaceutical, SL, AstraZeneca, Basilea Pharma, Baxter, BioLineRx Ltd., Celgene SLU, Eisai, Ipsen Pharma, Incyte; Financial Interests, Personal, Other, Direct research fund: Servier, Merck, Sharp & Dohme, Novocure, QED Therapeutics Inc., Roche, Sanofi-Aventis, Zymeworks; Financial Interests, Personal, Invited Speaker: Lilly, Janssen; Financial Interests, Institutional, Research Grant: Amc Medical Research, Armo Biosciences, Basilea, Biokeralty Research Institute, Merck Sharp & Dohme, Oncomed Pharmaceuticals, QED Therapeutics, VCN Biosciences, AbbVie Farmaceútica, Ability Pharmaceuticals, Agios, Amgen, Aslan, AstraZeneca, Bayer, BeiGene, BioLineRx, Blueprint Medicines, Boston Biomedical, Bristol Myers Squibb (BMS), Cantargia, Celgene, Eisai, Erytech Pharma, F. Hoffmann-La Roche, FibroGen, Genentech, Halozyme, Immunomedics, Incyte, Ipsen, Lab. Menarini, Lilly, Loxo Oncology, MedImmune, Merrimack, Millenium, Nelum, Novartis, Novocure, Pfizer, Pharmacyclics, Roche, Zymeworks; Non-Financial Interests, Member: American Society of Clinical Oncology - ASCO, “Sociedad Española de Oncología Médica” – SEOM, Sociedad Europea de Oncología Médica - ESMO; Other, Editorial Board: GI Annals og¡f Oncology. C.B. Westphalen: Financial Interests, Personal, Invited Speaker: Bayer, BMS, Celgene, GSK, Roche, Servier, Sirtex, Taiho, Chugai, Amgen, Falk, MSD, Merck, Janssen, AstraZeneca; Financial Interests, Personal, Advisory Board: BMS, Celgene, Shire/Baxalta, Rafael, RedHill, Roche, Janssen, Incyte; Financial Interests, Personal, Other, Travel Support: Bayer, Celgene, RedHill, Roche, Servier, Taiho, Janssen; Financial Interests, Personal and Institutional, Research Grant: Roche; Non-Financial Interests, Officer: AIO - Arbeitsgemeinschaft Internistische Onkologie (Germany); Non-Financial Interests, Advisory Role, Member of the EU Commission Mission Board for Cancer: EU Commission - DG RTD; Non-Financial Interests, Advisory Role, Member Forum Zukunftsstrategie: German Federal Ministry of Education and Research. G. Prager: Financial Interests, Personal, Advisory Board: Merck, Amgen, Servier, Bayer, Pierre Fabre, CECOG, Daiichi Sankyo Austria, AstraZeneca; Financial Interests, Personal, Invited Speaker: Roche, Sanofi, Lilly, BMS, MSD, Incyte; Financial Interests, Personal, Advisory Board, Advisory: Takeda; Financial Interests, Institutional, Local PI: Incyte, Servier, BMS, Novartis. H. Imaoka: Financial Interests, Personal, Invited Speaker: Yakult Honsha, AstraZeneca, Nihon Servier, Kaneka Medix, SB Kawasumi Laboratories, Boston Scientific, Novartis; Financial Interests, Personal, Advisory Board: Nihon Servier, Kaneka Medix; Financial Interests, Personal, Writing Engagement: Medico's Hirata; Financial Interests, Institutional, Local PI: Ono Pharmaceutical, Novartis, Nihon Servier. C. Verslype: Financial Interests, Personal, Advisory Board: Roche, Bayer, MSD; Financial Interests, Personal, Invited Speaker: Ipsen, Bayer; Financial Interests, Institutional, Research Grant, unrestricted: Bayer; Non-Financial Interests, Member, Lobby group: Pancreatic Cancer Europe. T. Okusaka: Financial Interests, Personal, Advisory Board: Eisai, Nihon Servier, AstraZeneca, Fujifilm Toyama Chemical; Financial Interests, Personal, Invited Speaker: AstraZeneca, Eisai, Chugai Pharma, Nihon Servier, Incyte, Novartis, Daiichi Sankyo, Taiho, Yakult, Myriad Genetics, Kyowa Kirin, Ono; Financial Interests, Institutional, Local PI: AstraZeneca, Eisai, Bristol Myers Squibb, Incyte, Syneos Health, Chiome Bioscience, Sysmex. F. Hedouin-Biville, B. Chevallier: Financial Interests, Personal, Full or part-time Employment: Servier. All other authors have declared no conflicts of interest.
Resources from the same session
1445P - Novel DNA methylation markers for early detection of cardia gastric adenocarcinoma and esophageal squamous cell carcinoma
Presenter: Zhiyuan Fan
Session: Poster session 18
Resources:
Abstract
1447P - Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Presenter: David Tougeron
Session: Poster session 18
1448P - IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts
Presenter: Christelle de la Fouchardiere
Session: Poster session 18
1449P - Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
Presenter: Markus Moehler
Session: Poster session 18
1450P - Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial
Presenter: Georg Martin Haag
Session: Poster session 18
1453P - A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)
Presenter: Nan Bi
Session: Poster session 18
1454P - An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)
Presenter: Akihito Kawazoe
Session: Poster session 18